William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how the COVID-19 pandemic has had an impact on the seasonality of respiratory syncytial virus (RSV).
William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how the COVID-19 pandemic has had an impact on the seasonality of respiratory syncytial virus (RSV).
Transcript
How has the COVID-19 pandemic impacted the normal seasonality of respiratory syncytial virus?
Stinchfield: The COVID-19 pandemic has disrupted a lot of things, including other viruses, some of which have had to take a backseat to this virus. RSV season, as we typically see it in the fall and winter, was definitely disrupted. At the beginning of the pandemic, we saw some coinfections in children—both RSV and SARS-CoV-2, or influenza [and] SARS-CoV-2, a little bit of influenza and RSV. The second winter, though, we really didn't see much RSV and then, very strangely, RSV reemerged in the summer unexpectedly and with a vengeance. The pediatric population has quieted down, and now when it's supposed to be high right now, it's really not as much of a factor.
Schaffner: And that's been true largely across the country, because it's happened exactly as Patsy's described in Minnesota [and] that's exactly what's happened here in Tennessee. RSV has come early, disappeared early, or almost disappeared early. We're looking forward to reviewing our data to see how many coinfections we will find of both RSV and COVID at the same time. How frequent is it? Can we distinguish these patients from others? Do they produce more severe disease when they are present at the same time? Those are questions that are still unanswered.
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
Chronic Respiratory Diseases Linked to Other Noncommunicable Diseases in Vulnerable Countries
August 4th 2025Despite their devastating global impact, chronic respiratory diseases remain a hidden threat in low- and middle-income countries, often going undiagnosed in adults who are already battling other noncommunicable diseases.
Read More